Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4655062 | 0.87 | MEN1 (0.36) | MEN1KMT2AEPHX2SCN4ANPY1R | |
| SCHEMBL4655144 | 0.84 | SIRT2 (0.34) | MEN1KMT2ASIRT2EPHX2SCN4A | |
| SCHEMBL4654027 | 0.81 | MEN1 (0.39) | MEN1KMT2AEPHX2SCN4ANPY1R | |
| SCHEMBL4655132 | 0.76 | ALDH1A1 (0.37) | MEN1KMT2AEPHX2 | |
| SCHEMBL4654124 | 0.76 | PIM1 (0.37) | MEN1KMT2ASIRT2KIF11 | |
| SCHEMBL1033672 | 0.74 | NPY1R (0.35) | MEN1KMT2AEPHX2SCN4ANPY1R | |
| SCHEMBL1033037 | 0.73 | NPY1R (0.36) | MEN1KMT2AEPHX2SCN4ANPY1R | |
| SCHEMBL20292475 | 0.70 | LMNA (0.32) | MEN1KMT2A | |
| SCHEMBL28173587 | 0.70 | RORA (0.36) | MEN1KMT2AEPHX2SCN4AHRH4 | |
| SCHEMBL4654150 | 0.70 | PTGDR2 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1740568-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORP (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | SMITHKLINE BEECHAM CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1740568-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE. | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005077926-A2 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155805-A1 | Benzofuran and bezothiophene derivatives useful for the treatment of cardiovascular disease | ABAT, BPTF, TNNT2 | MEN1 3656/4885KMT2A 1404/4885SIRT2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.